SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Achilles Therapeutics plc (ACHL) .
本页证实的标准:
- VALUE (90/100, 通过) — 分析师目标价暗示上行空间 (+35.1%).
- 分析师共识目标价 $2.00 (+35.1% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分: 46/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
90/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ACHL
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.74
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$2.00 (+35.1%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS(稀释) |
营收 |
净利润 |
净利润率 |
| 2018 |
$-12.69 |
$0.00 |
$-6.89M |
- |
| 2019 |
$-8.52 |
$0.00 |
$-13.99M |
- |
| 2020 |
$-0.82 |
$0.00 |
$-33.2M |
- |
| 2021 |
$-2.13 |
$0.00 |
$-61.1M |
- |
| 2022 |
$-1.82 |
$0.00 |
$-71.18M |
- |
| 2023 |
$-1.74 |
$0.00 |
$-69.67M |
- |